BioWorld MedTech

July 7, 2015

Hansen gets bump to start ARTISAN: Hansen Medical completes enrollment in initial cohort of ARTISAN clinical trial

Coming off a 5.07% bump in its shares last week, intravascular robotics specialist Hansen Medical (NASDAQ: HNSN) (Mountain View, Calif.) said it has completed enrollment in the initial evaluable cohort of its ARTISAN clinical trial. Read More

Two patents invalidated: Fed Circuit: 'Experimental' manufacturing dooms patents

Latin America: British device aker looks to ride LatAm growth

Inside the Beltway: Economic impact report makes implicit argument for repeal of device tax

Report from Europe: EU Council readies CE mark reform for 'trialogue' negotiation

Daily M&A: Vygon Group buys Preouse to upgrade vascular access

Financings: Lantheus closes initial public offering,brings in nearly $66.7 million

World in Review: Lensar moves into Indian market, establishing Sharp Sight Centers

Products

Court Report: Enzo Biochem reaches $7.1M settlement with Luminex

People in Places

Briefly noted

MDD's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for May 26, 2026

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma

BioWorld Science

Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...